The words of Andres Manuel López Obrador occur when, according to official figures, El Salvador records: 56,653 confirmed cases of Covid-19, and 1,727 deaths from this cause
The President of Mexico, Andrés Manuel López Obrador, lamented that Central American countries such as Guatemala, Honduras and El Salvador do not yet have the Covid-19 vaccine.
“It is unfortunate that Central American countries, like many other countries in the world, are affected and that they do not have access to the vaccine. That Guatemala Honduras, El Salvador do not have access to the vaccine. How much vaccine is required to to protect these brothers? Well, no, because the population is not large. We must have a vision of solidarity and there must be universal brotherhood, “López Obrador emphasized during his morning press conference.
You may be interested in: Government paid $ 12,600 with El Salvador hospital funds for publications in international journals
López Obrador’s words occur when, according to official figures, El Salvador records: 56,653 confirmed cases of Covid-19, 1,727 deaths from this cause and 3,927 active cases.
In addition, the Mexican president called on the international community to “think about our fellow human beings” and that this allows vaccines to reach Central American countries. In the region, only Costa Rica and Panama have received, and already applied, doses of the Pfizer vaccine.
Waiting and no date for the arrival of vaccines
El Salvador is waiting for the arrival of four different types of vaccines for immunization against Covid-19.
At the end of November last year the government announced that two million doses would come from the pharmaceutical company AstraZeneca, it was not reported on the names of the other three companies, except on when they would arrive in the country.
Read also: Report shows saturation in El Salvador hospital
The vaccine from AstraZeneca and the University of Oxford has a lower cost and more favorable conditions for storage, transport and logistics, compared to other competitors, such as the alliance between the American pharmaceutical company Pfizer and the German BioNTech.
These are much more expensive to manufacture and require low temperature refrigeration which makes their marketing and distribution difficult especially in low income countries globally.